Document is current
Any future updates will be listed below
-
Authors
Toikumo, Sylvanus
Xu, Heng
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Kember, Rachel L. https://orcid.org/0000-0001-8820-2659
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (AA02636, AA028292)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA046345)
- License Information
-
More Information
Article History
Received: 4 March 2022
Revised: 13 June 2022
Accepted: 16 July 2022
First Online: 8 August 2022
Competing interests
: HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. JG and HRK are holders of U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” issued 26 January 2021. The other authors have no disclosures to make.
